Drug discovery is a process involving multiple disciplines and interests. During the research phase of drug discovery, usually a large number of compounds are evaluated for biological activity and toxicological potential in animal species. Various types of problems with respect to pharmacodynamics, pharmacokinetics, and toxicity are commonly encountered at this stage. Drug metabolism, as a discipline participating in a drug discovery team, can play an important role in identifying factors underlying the problems, facilitate the optimal selection of compounds for further development, provide information on metabolites for possible improvement in drug design, and contribute to the identification of the appropriate animal species for subsequent toxicity testing. During the process of evaluating oxytocin receptor antagonists for further development for treatment of preterm labor, in vivo and in vitro drug metabolism studies conducted in rats, dogs, and monkeys contributed to the selection of L-368,899 as the development candidate on the basis of pharmacokinetic and metabolism observations. The presence of active N-demethylated metabolites of two other equipotent compounds in rats and dogs was found to be the major factor responsible for the discrepancy between oral bioavailability and efficacies observed for these 2 compounds. For L-368,899, a compound that demonstrated 20-40% oral bioavailability in rats, dogs, and chimpanzees, extensive first-pass metabolism rather than absorption was determined as the major factor responsible for the poor bioavailability (< 1%) in rhesus monkeys. In vitro metabolism studies with hepatic microsomes from rats, dogs, monkeys, and humans substantiated the conclusion that the rate of hepatic metabolism of L-368,899 in monkeys is faster than in the other species.
INTRODUCTION
The drug discovery phase discussed here refers to the research phase during which new chemical entities are prepared and investigated either for the modulation of some aspects of physiological functions that may have direct relationship to a diseased state or for the modification of some biochemical processes with therapeutic potential yet to be defined. This phase is the first part of the lengthy and expensive process of developing new drugs; it is a collaborative effort involving many disciplines and interests that has been described as a long-range task with the potential for considerable medical and scientific benefits and a high risk of failure (10, 16, 21 ) . The various types of failures commonly encountered at this stage include, but are not limited to, the lack of correlation between in vitro activity and in vivo efficacy or between pharmacodynamics and pharmacokinetics in animal models, the deficiency in duration of pharmacological action, or having adverse effects in animals at high dose or after multiple doses. Drug metabolism, as a discipline participating in a drug discovery team, can play an important role in identifying factors underlying the problems, facilitate the optimal selection of compounds for further development, provide information on metabolites for possible improvement in drug design, and contribute to the identification of the appropriate animal species for subsequent toxicity testing.
DRUG METABOLISM STUDIES AT THE RESEARCH PHASE
It should be recognized that the drug discovery phase is characteristic in that a large number of compounds are usually being evaluate for biological activity, toxicity, or pharmacokinetics within a relatively short period of time. Furthermore, the compounds are usually available only in limited quantities and rarely are radiolabeled compounds available. The design of drug metabolism studies, therefore, usually reflects requirements and limitations characteristic of this phase. In general, pharmacokinetic study protocols are usually much less comprehensive than desired, methods of quantification are adequate but frequently have not been perfected to achieve the highest sensitivity possible, and in vitro cell or organ preparations from various animal species are used extensively for the evaluation of compounds with respect to relative stability, absorption, or metabolic pathways. In vitro systems derived from humans are often included if available, with the goal of identifying the animal species more closely related to humans from the perspectives of metabolism and pharmacokinetics.
The involvement of drug metabolism in the selection of a nonpeptidyl oxytocin (OT) receptor antagonist for development will serve as a case study.
OT PRECEPTOR ANTAGONIST
The neurohypophyseal nonapeptide hormone OT has been shown to be important in the initiation and progression of labor and the potential use of OT receptor antagonist has been proposed ( 1, 2, 4, 5, 8, 9, 12) . Although several distinct classes of potent peptidyl OT antagonists have been reported, it was not until recently that orally active nonpeptidyl antagonists have been discovered (7, 11, 15, 20) . These nonpeptidyl antagonists are represented by lead structures containing spiroindenylpiperidinecamphor-sulfonamide moieties (3, 6, 14) . Further modification of these structures with potencyenhancing groups led to a group of potent, selective antagonists represented by Compounds I (L-368,899), II, and III ( Fig. 1 ) ( 13, 19) . As shown, the OT antagonistic activities of these 3 compounds as measured in vitro by competitive binding to OT receptors in rat and human uterine tissues were comparable with K, values ranging from 2 to 13 nM.
The compounds are also active in iii<> in the inhibition of OT-stimulated uterine contractions of nonpregnant rats after iv infusion or id (intraduodenal) injection (AD5o)' With comparable pharmacological activities and physical properties (e.g., solubility), pharmacokinetics and metabolism of these compounds remained to be evaluated and subsequentlv show-n to be the important criteria for the selection of Compound I. or L-368.899. as the development candidate.
COMPARISON OF ORAL BIOAYAILABILITY -BIOASSAY VERSUS CHEMICAL ASSAY
The oral bioavailability of L-368,899, II, and III was studied in female Sprague-Dawley rats. The animals were serially bled following either an iv (5 mg/ kg) or po (20 mg/kg) dose, and plasma levels of unchanged drug were determined by a high-performance liquid chromatography (HPLC) assay monitored with ultraviolet (UV) absorbance. Following iv dosing, L-368,899 exhibited the highest plasma levels at all time points and the slowest clearance ( Fig. 2 ). Following oral dosing, there was a significant difference in the area under the plasma concentration-time curve (AUCo_6hf) among the 3 compounds with the AUC of L-368,899 being at least 10 times higher than that of Compounds II and III (Fig. 2 ). The resulting bioavailability was -40% for L-368,899 and ~ 5% for the other 2 compounds. On the basis of these results, it appeared that the low bioavailability of Compounds II and III might have been the consequence of extensive first-pass metabolism and/or poor absorption. These results were substantially difl'erent from those obtained from the in situ studies with id-dosed rats in which plasma OT antagonistic activity was assayed by radioligand binding. Results from those studies indicated that all 3 compounds had more or less equal functional bioavailability. We suspected that the discrepancy might have been due to either procedural differences (dosing route, dosing vehicle, and blood sampling method) or the presence of active metabolites of Compounds II and III in rat plasma and decided to repeat the study with identical dose (iv at 3 mg/kg and po at 10 mgr'kg), formulation (dimethyl sulfoxide/emulphor/saline, 1 ~:15:7a), and protocols used in the pharmacological experiments. In the repeat experiments, all plasma samples were divided into 2 portions so that chemical (HPLC) and radioligand binding assays could be done in parallel. In addition, HPLC column-effluent fractions corresponding to the parent compound and more polar regions were collected and assayed for OT receptor antagonistic activity. Results showed that. in general, plasma concentrations of OT antagonistic activity were higher (1-2 times) than that b-, HPLC assay: howe~°er, the difference was exceedingly high (5- Compound II also indicated that there was OT antagonistic activity eluting at 2 metabolite regions designated as M and M2. The retention time of M2 was similar to that of L-368,899, and M1 was identified as the monodemethylated Compound II, i.e., the monomethylated derivative of L-368,899 ( Fig. 3 ). Reexamination of plasma samples from previous studies of Compounds II and III also showed similar profiles of metabolites. For Compound III, the corresponding metabolites were M2, the desmethylated compound, and M 1, the monodemethylated derivative of the parent Compound III.
Subsequent to the rat studies, similar studies were conducted in dogs, dosed iv at 5 mg/kg and orally at 20 mg/kg. Results showed that for L-368,899, drug levels assayed by HPLC were --50-100% of that by bioassay, regardless of the dosing route. For Compound II, however, the discrepancy was significantly large following oral dosing; drug levels by HPLC ranged between 6 and 28% of that by bioassay. The presence of M 1 and M2 were also detected in HPLC column-effluent fractions by bioassay and by UV detection. Oral bioavailability of L-368,899 and Compound II were 21 and 5%, re-spectively. Low bioavailability of -5% was also obtained for Compound III. Further comparison of pharmacokinetics and pharmacodynamics of the 3 compounds was also carried out in the rhesus monkey, the species in which the functional activity of an OT antagonist would be tested eventually. Despite the fact that all 3 compounds exhibited comparable ADso in the pregnant rhesus monkey (I, 27 ,ug/kg; II, 45 >g/kgj and III, 35 Ag/kg) following iv infusion at 25 >g/kg/min for 2 hr, L-368,899 showed the highest plasma concentrations relative to total antagonistic activity with levels accounting for > 85% of the bioactivity throughout infusion and -60% postinfusion. The corresponding levels were much lower for Compounds II and III, at -50% during infusion and < 30% postinfusion. Metabolites that chromatographed similarly to M 1 and M2 of each compound were also detected in monkey plasma for Compounds II and III. On the basis of the in vivo studies in the rat, dog, and monkey, it was concluded that rapid first-pass N-demethylation of Compounds II and III was the major factor leading to the much lower bioavailability in rats and dogs observed for these 2 compounds compared to L-368,899. (L-368,899) , II, and III in female rats following iv ( 10 mg/kg) and po dosing (20 mg/kg).
COMPARISON OF INTRINSIC METABOLIC STABILITY
To compare the intrinsic metabolic potential of L-36$,$99, II, and III in vitro, especially with respect to N-demethylation. each compound (50 ~M) was incubated with hepatic microsomes from both genders of rats, dogs, and rhesus monkeys ( mg pro-te~n; m1) in the presence ot an iSAUrH regeneratmg system. Compared to L-368,899. which showed reasonable stability, except for female dog and male rat. Compound II was extensively metabolized in monkey hepatic microsomes (4% remaining after 40 min). The monometh,. I deri ;ati , e ; ('At 1) was the major metabolite detected in the microsomal incubates of dogs and rats. w hereas both 1,~ 1 and the des- On the basis of pharmacokinetics and the extensive metabolism observed for both Compounds II and III, together with additional considerations that L-368,899 has excellent affinity and selectivity for human OT versus arginine vasopressin receptors ( Fig. 1 ) and higher water solubility, the other 2 compounds were eliminated from consideration as development candidates (14, 19) .
PROBLEM IN RHESUS MONKEY: ABSORPTION OR METABOLISM?
To continue with the evaluation of L-368,899 as a final choice for development, the compound was studied further in the rhesus monkey to determine its oral bioavailability. The results obtained following oral dosing of L-368,899 was rather unexpected; bioavailability based on radioligand binding assay was < 5%. Subsequent pharmacokinetic studies confirmed the results in both fasted and fed animals.
Following oral dosing at 20 mg/kg, plasma concentrations of L-368,899 were < 100 ng/ml within 1 hr and were below the detection limit (5 ng/ml) after 1 hr with bioavailability estimated to be < 1%. The challenge thereafter was to determine the factor(s) responsible for the poor bioavailability observed in this species: Is it poor absorption or extensive metabolism ?
We decided to study this problem by dosing monkeys orally with ['4C]L-368,899 in addition to the radiolabeled studies already in progress then in rats and dogs. Results collected from rats showed that following iv dosing the majority (80%) of the dose was excreted in the feces. Following oral dosing, the radioactive dose was largely excreted in feces and about 10% of the dose was eliminated in the urine.
Similar results were obtained in dogs and monkeys, suggesting that absorption was at least 10%. Total radioactivity AUC in plasma following oral dosing was -50% of that after iv dosing. When the fecal radioactivity profiles were compared among species, it was apparent that metabolite profiles were similar qualitatively in all species with the presence of only low levels of intact parent, suggesting that there was not a large portion of intact, unabsorbed drug. In addition, plasma radioactivity profiles from monkeys were similar to that of rat plasma from later time points and feces, suggesting that they probably consisted of similar metabolites. Analysis of urinary radioactivity from monkeys showed that > 50% was due to a polar compound identified as [14C]methionine sulfone by comparison with the authentic compound and by chemical derivatization. When ['4C]L-368,899 was incubated with monkey liver S9 TABLE I. -In ritro metabolism of L-368-899 by liver microsomes from rats. monkens. and humans. a Incubations were carried out at 0.5 mg protein/ml for 10 min with microsomes prepared from composite livers from rats, monkeys, and individual livers from human subjects. All values were averages of duplicate incubations. The percentage of parent compound remaining was calculated based on the ratio of peak areas of products and the parent compound. fractions, monkey liver slices, and rat hepatocytes, a polar ('4C]-labeled metabolite with retention time similar to that of methionine sulfone was also detected, albeit at low levels, suggesting that this reaction could probably be catalyzed by hepatic enzymes. Further in vitro metabolism studies with liver microsomes supported the postulate that hepatic metabolism may be one of the major factors contributing to the low bioavailability in monkeys. In these studies, it was shown that the rate of hepatic metabolism of L-368,899 in monkey liver microsomes was much more rapid than that in rats, dogs, and humans (Table I) .
Results from in vivo and in vitro metabolism studies, when taken together, led to the following conclusions : (a) absorption of the oral dose in monkeys was at least 10-30% estimated on the basis of radioactivity recovered in urine and plasma; (b) L-368,899 underwent extensive first-pass metabolism in the monkey after oral dosing, and liver is one of the likely major sites ofmetabolism; (c) major metabolites from monkey, rat, and dog recovered in feces chromatographed similarly to mono-and dihydroxylated L-368,899 (these compounds were largely the result of hepatic biotransformation); (d) cleavage of the methionine sulfone was a minor metabolic pathway in both monkey and rat (of the 10% radioactive dose recovered in urine, at least 50% was due to methionine sulfone); and (e) liver microsomes from monkeys can metabolize L-368,899 at a much faster rate than those from rats. dogs, and humans. These conclusions have been confirmed in later experiments in which pharmacokinetic parameters and metabolism of L-368,899 were characterized more thoroughly ( 17, 18) .
To collect additional supporting evidence with respect to the conclusion that absorption of L-368,899 is not a problem in primates, a separate experiment was conducted in chimpanzees in which 2 animals were dosed iv 5 mg/kg and po at 20 mg/ kg. Oral bioavailability of L-368,899 was shown to be 13 and 20%, indicating that the poor bioavailability observed in the rhesus monkey is not representative of the primates for this compound. Currently, L-368,899 is undergoing Phase I clinical testing with the primary goal of demonstrating safety and tolerability.
CONCLUSION
The presence of active N-demethylated metabolites of Compounds II and III was found to be the major factor responsible for the discrepancy between oral bioavailability determined by chemical assay and functional bioavailability measured by OT radioligand binding in rats, dogs, and monkeys.
As a result, Compound I (L-368,899) was selected for development among the 3 compounds. In rats, dogs, and chimpanzees, oral bioavailability of L-368,899 was 20-40%; it was below 1°lo in rhesus monkeys largely due to extensive first-pass metabolism. Results from in vitro metabolism studies with hepatic microsomes from rats, dogs, monkeys, and humans substantiated the conclusion that the rate of hepatic metabolism of L-368,899 by monkeys is faster than the other species.
